Lung cancer study tests immune drug to keep disease at bay
NCT ID NCT04418648
First seen Feb 04, 2026 · Last updated Apr 24, 2026 · Updated 14 times
Summary
This study looked at whether the drug toripalimab, given after standard chemoradiation, could help people with limited-stage small cell lung cancer live longer without their cancer getting worse. The trial enrolled 170 adults aged 18-75 whose cancer had not grown after initial treatment. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER LIMITED STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, 510060, China
Conditions
Explore the condition pages connected to this study.